Director dealings

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                               Director dealings                               

Bioventix plc (AIM: BVXP) was notified on 22 October 2014 that on the same day,
due to institutional investor demand, the following directors dealt in the
ordinary shares of 5 pence each ("Ordinary Shares") in the Company:

Name       Position         Type of       Number    Price    Ordinary  Percentage
                            transaction       of      per  shares and of Ordinary
                                        Ordinary Ordinary      voting  Shares and
                                          Shares    Share rights held      voting
                                                  (pence)   following rights held
                                                                  the   following
                                                          transaction         the
                                                                      transaction
                                                                                 
Ian        Non-Executive    Disposal      8,000*    655.0      32,000         0.6
Nicholson  Chairman                                                              
                                                                                 
Peter      Chief Executive  Disposal    80,000**    655.0     761,176        15.1
Harrison                                                                         

*    4,000 of which were held in the name of his wife          
                                                               
**   25,000 of which were held in the name of his wife         


For further information please contact:

Bioventix plc                                         Tel: [phone]       
Peter Harrison             Chief Executive Officer                                                        
                                                                               
finnCap Ltd                                           Tel: [phone]       
Geoff Nash/Simon Hicks     Corporate Finance                                   
Steve Norcross             Corporate Broking                                   

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.